The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Distinct Requirements for IFNs and STAT1 in NK Cell Function
Open accessAbstract
NK cell functions were examined in mice with a targeted mutation of the STAT1 gene, an essential mediator of IFN signaling. Mice deficient in STAT1 displayed impaired basal NK cytolytic activity in vitro and were unable to reject transplanted tumors in vivo, despite the presence of normal numbers of NK cells. IL-12 enhanced NK-mediated cytolysis, but poly(I:C) did not, and a similar phenotype occurred in mice lacking IFNα receptors. Molecules involved in activation and lytic function of NK cells (granzyme A, granzyme B, perforin, DAP10, and DAP12) were expressed at comparable levels in both wild-type and STAT1−/− mice, and serine esterase activity necessary for CTL function was normal, showing that the lytic machinery was intact. NK cells with normal cytolytic activity could be derived from STAT1−/− bone marrow progenitors in response to IL-15 in vitro, and enhanced NK lytic activity and normal levels of IFN-γ were produced in response to IL-12 treatment in vivo. Despite these normal responses to cytokines, STAT1−/− mice could not reject the NK-sensitive tumor RMA-S, even following IL-12 treatment in vivo. Whereas in vitro NK cytolysis was also reduced in mice lacking both type I and type II IFN receptors, these mice resisted tumor challenge. These results demonstrate that both IFN-α and IFN-γ are required to maintain NK cell function and define a STAT1-dependent but partially IFN-independent pathway required for NK-mediated antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 3×
“Although the ability of tumor cells to respond directly to IFN-g can play a major role in tumor surveillance (32), the impaired rejection of IFN-responsive tumor cells observed here would require a host defect, for instance, impaired IFNg production.”
BackgroundImpaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice
Kaplan, M. H., Sun, Y.-L., Hoey, T., & Grusby, M. J. (1996) · Nature · doi:10.1038/382174a0 · Cited by 1,240
Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., & Kerr, I. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06106.x · Cited by 411
Cited by
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Self-citationRegulation of Interferon‐γ During Innate and Adaptive Immune Responses
(2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96002-2 · Cited by 1,655
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
O'Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119
Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente
García-Sastre, A., & Biron, C. A. (2006) · Science · doi:10.1126/science.1125676 · Cited by 885
Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency
Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I. Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., et al. (2003) · Nature Genetics · doi:10.1038/ng1097 · Cited by 816
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Interferons α and β as Immune Regulators—A New Look
Biron, C. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00154-6 · Cited by 667
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M., & Nestle, F. O. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031482 · Cited by 522
Direct Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Self-citationSTING Agonists as Cancer Therapeutics
Amouzegar, A., Chelvanambi, M., Filderman, J., Storkus, W., & Luke, J. (2021) · Cancers · doi:10.3390/cancers13112695 · Cited by 395
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
Roles of unphosphorylated STATs in signaling
Yang, J., & Stark, G. R. (2008) · Cell Research · doi:10.1038/cr.2008.41 · Cited by 347
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 339
Direct Antiviral Mechanisms of Interferon-Gamma
Kang, S., Brown, H. M., & Hwang, S. (2018) · Immune Network · doi:10.4110/in.2018.18.e33 · Cited by 272
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264
Lee, C.-K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Takeshita, K., DePinho, R. A., & Levy, D. E. (2002) · Immunity · doi:10.1016/s1074-7613(02)00336-9 · Cited by 242
Self-citationInterferons: Signaling, antiviral and viral evasion
Bonjardim, C. A., Ferreira, P. C. P., & Kroon, E. G. (2009) · Immunology Letters · doi:10.1016/j.imlet.2008.11.002 · Cited by 196
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
“Stat1 activation has been shown to be critical for NK antitumor activity (22).”
Metadata
- Authors
- Lee, C.-K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B., & Levy, D. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-10-01
- Volume
- 165
- Issue
- 7
- Pages
- 3571-3577
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1778677407
- Cited by
- 217
- References
- 3
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.